Mast cells are required for the development of renal fibrosis in the rodent unilateral ureteral obstruction model

American Journal of Physiology - Renal Physiology

Volumn 302, Issue 1, 2012, Pages 192-204

  Veerappan, Arul ^a   Reid, Alicia C ^a   O'Connor, Nathan ^a   Mora, Rosalia ^a   Brazin, Jacqueline A ^a   Estephan, Racha ^a   Kameue, Takashi ^a   Chen, Jie ^a   Felsen, Diane ^a   Seshan, Surya V ^a   Poppas, Dix P ^a   Maack, Thomas ^a   Silver, Randi B ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Angiotensin; Isolated; Perfused kidney; Tubulointerstitiial fibrosis

Indexed keywords

ANGIOTENSIN II; COLLAGEN; CROMOGLYCATE DISODIUM; LOSARTAN; PEPSIN A; RENIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; CELL COUNT; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; KIDNEY FIBROSIS; KIDNEY VASCULAR RESISTANCE; MALE; MAST CELL; MAST CELL DEGRANULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; URETER OBSTRUCTION;

EID: 83455223823     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00562.2010     Document Type: Article

References (57)

1. Bergstresser PR, Tigelaar RE, Tharp MD. Conjugated avidin identifies cutaneous rodent and human mast cells. J Invest Dermatol 83: 214-218, 1984.
2. Blank U, Essig M, Scandiuzzi L, Benhamou M, Kanamaru Y. Mast cells and inflammatory kidney disease. Immunol Rev 217: 79-95, 2007.
3. Chevalier RL, Forbes MS, Thornhill BA. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 75: 1145-1152, 2009.
4. Chevalier RL, Thornhill BA, Gomez RA. EDRF modulates renal hemodynamics during unilateral ureteral obstruction in the rat. Kidney Int 42: 400-406, 1992.
5. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, Gamradt M, Rhys CM, Holm TM, Loeys BL, Ramirez F, Judge DP, Ward CW, Dietz HC. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 13: 204-210, 2007.
6. Colvin RB, Dvorak AM, Dvorak HF. Mast cells in the cortical tubular epithelium and interstitium in human renal disease. Hum Pathol 5: 315-326, 1974.
7. De Mello G, Maack T. Nephron function of the isolated perfused rat kidney. Am J Physiol 231: 1699-1707, 1976.
8. Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol 15: 290-301, 2000.
9. Ehara T, Shigematsu H. Contribution of mast cells to the tubulointerstitial lesions in IgA nephritis. Kidney Int 54: 1675-1683, 1998.
10. Ehara T, Shigematsu H. Mast cells in the kidney. Nephrology (Carlton) 8: 130-138, 2003.
11. el-Dahr SS, Gee J, Dipp S, Hanss BG, Vari RC, Chao J. Upregulation of renin-angiotensin system and downregulation of kallikrein in obstructive nephropathy. Am J Physiol Renal Fluid Electrolyte Physiol 264: F874-F881, 1993.
12. El-Koraie AF, Baddour NM, Adam AG, El Kashef EH, El Nahas AM. Role of stem cell factor and mast cells in the progression of chronic glomerulonephritides. Kidney Int 60: 167-172, 2001.
13. Fern RJ, Yesko CM, Thornhill BA, Kim HS, Smithies O, Chevalier RL. Reduced angiotensinogen expression attenuates renal interstitial fibrosis in obstructive nephropathy in mice. J Clin Invest 103: 39-46, 1999.
14. Furuichi K, Gao JL, Murphy PM. Chemokine receptor CX3CR1 regulates renal interstitial fibrosis after ischemia-reperfusion injury. Am J Pathol 169: 372-387, 2006.
15. Galli SJ. New concepts about the mast cell. N Engl J Med 328: 257-265, 1993.
16. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol 23: 749-786, 2005.
17. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312: 117-121, 2006.
18. Hackenthal E, Hackenthal R, Hilgenfeldt U. Isorenin, pseudorenin, cathepsin D and renin. A comparative enzymatic study of angiotensinforming enzymes. Biochim Biophys Acta 522: 574-588, 1978.
19. Hirsch AT, Opsahl JA, Lunzer MM, Katz SA. Active renin and angiotensinogen in cardiac interstitial fluid after myocardial infarction. Am J Physiol Heart Circ Physiol 276: H1818-H1826, 1999.
20. Ibels LS, Gyory AZ. IgA nephropathy: analysis of the natural history, important factors in the progression of renal disease, and a review of the literature. Medicine (Baltimore) 73: 79-102, 1994.
21. Isaka Y, Tsujie M, Ando Y, Nakamura H, Kaneda Y, Imai E, Hori M. Transforming growth factor-beta 1 antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction. Kidney Int 58: 1885-1892, 2000.
22. Ishidoya S, Morrissey J, McCracken R, Reyes A, Klahr S. Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 47: 1285-1294, 1995.
23. Jones SE, Kelly DJ, Cox AJ, Zhang Y, Gow RM, Gilbert RE. Mast cell infiltration and chemokine expression in progressive renal disease. Kidney Int 64: 906-913, 2003.
24. Kim DH, Moon SO, Jung YJ, Lee AS, Kang KP, Lee TH, Lee S, Chai OH, Song CH, Jang KY, Sung MJ, Zhang X, Park SK, Kim W. Mast cells decrease renal fibrosis in unilateral ureteral obstruction. Kidney Int 75: 1031-1038, 2009.
25. Klahr S, Ishidoya S, Morrissey J. Role of angiotensin II in the tubulointerstitial fibrosis of obstructive nephropathy. Am J Kidney Dis 26: 141-146, 1995.
26. Klahr S, Morrissey J. Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol 283: F861-F875, 2002.
27. Kokkonen JO, Kovanen PT. Low-density-lipoprotein binding by mastcell granules. Demonstration of binding of apolipoprotein B to heparin proteoglycan of exocytosed granules. Biochem J 241: 583-589, 1987.
28. Konishi Y, Morikawa T, Okada N, Maeda I, Kitabayashi C, Yoshioka K, Okumura M, Nishiyama A, Ueda M, Takai S, Miyazaki M, Imanishi M. Evidence for abundant presence of chymase-positive mast cells in the kidneys of patients with immunoglobulin A nephropathy: effect of combination therapy with prednisolone and angiotensin II receptor blocker valsartan. Hypertens Res 31: 1517-1524, 2008.
29. Liu C, Wilson SJ, Kuei C, Lovenberg TW. Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation. J Pharmacol Exp Ther 299: 121-130, 2001.
30. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 69: 213-217, 2006.
31. Maack T. Physiological evaluation of the isolated perfused rat kidney. Am J Physiol Renal Fluid Electrolyte Physiol 238: F71-F78, 1980.
32. Mackins CJ, Kano S, Seyedi N, Schafer U, Reid AC, Machida T, Silver RB, Levi R. Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/ reperfusion. J Clin Invest 116: 1063-1070, 2006.
33. Martin MM, Buckenberger JA, Jiang J, Malana GE, Knoell DL, Feldman DS, Elton TS. TGF-β1 stimulates human AT1 receptor expression in lung fibroblasts by cross talk between the Smad, p38 MAPK, JNK, and PI3K signaling pathways. Am J Physiol Lung Cell Mol Physiol 293: L790-L799, 2007.
34. Matoba T, Murakami K, Inagami T. Rat renin: purification and characterization. Biochim Biophys Acta 526: 560-571, 1978.
35. Miyazawa S, Hotta O, Doi N, Natori Y, Nishikawa K. Role of mast cells in the development of renal fibrosis: use of mast cell-deficient rats. Kidney Int 65: 2228-2237, 2004.
36. Navar LG. The intrarenal renin-angiotensin system in hypertension. Kidney Int 65: 1522-1532, 2004.
37. Navar LG, Harrison-Bernard LM, Imig JD, Wang CT, Cervenka L, Mitchell KD. Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade. J Am Soc Nephrol 10, Suppl 12: S266-S272, 1999.
38. Navar LG, Harrison-Bernard LM, Wang CT, Cervenka L, Mitchell KD. Concentrations and actions of intraluminal angiotensin II. J Am Soc Nephrol 10, Suppl 11: S189-S195, 1999.
39. Navar LG, Nishiyama A. Why are angiotensin concentrations so high in the kidney? Curr Opin Nephrol Hypertens 13: 107-115, 2004.
40. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 109: 1417-1427, 2002.
41. Pavone-Macaluso M. Tissue mast cells in renal diseases. Acta Pathol Microbiol Scand 50: 337-346, 1960.
42. Phillips MI, Speakman EA, Kimura B. Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. Regul Pept 43: 1-20, 1993.
43. Roberts IS, Brenchley PE. Mast cells: the forgotten cells of renal fibrosis. J Clin Pathol 53: 858-862, 2000.
44. Ruger BM, Hasan Q, Greenhill NS, Davis PF, Dunbar PR, Neale TJ. Mast cells and type VIII collagen in human diabetic nephropathy. Diabetologia 39: 1215-1222, 1996.
45. Ruiz-Ortega M, Egido J. Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int 52: 1497-1510, 1997.
46. Schwertschlag U, Hackenthal E. Histamine stimulates renin release from the isolated perfused rat kidney. Naunyn Schmiedebergs Arch Pharmacol 319: 239-242, 1982.
47. Seikaly MG, Arant BS Jr, Seney FD Jr. Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J Clin Invest 86: 1352-1357, 1990.
48. Silver RB, Reid AC, Mackins CJ, Askwith T, Schaefer U, Herzlinger D, Levi R. Mast cells: a unique source of renin. Proc Natl Acad Sci USA 101: 13607-13612, 2004.
49. Simoneau B, Lavallee P, Anderson PC, Bailey M, Bantle G, Berthiaume S, Chabot C, Fazal G, Halmos T, Ogilvie WW, Poupart MA, Thavonekham B, Xin Z, Thibeault D, Bolger G, Panzenbeck M, Winquist R, Jung GL. Discovery of non-peptidic P2-P3 butanediamide renin inhibitors with high oral efficacy. Bioorg Med Chem 7: 489-508, 1999.
50. Tharp MD, Seelig LL Jr, Tigelaar RE, Bergstresser PR. Conjugated avidin binds to mast cell granules. J Histochem Cytochem 33: 27-32, 1985.
51. Timoshanko JR, Kitching R, Semple TJ, Tipping PG, Holdsworth SR. A pathogenetic role for mast cells in experimental crescentic glomerulonephritis. J Am Soc Nephrol 17: 150-159, 2006.
52. Unger T, Badoer E, Ganten D, Lang RE, Rettig R. Brain angiotensin: pathways and pharmacology. Circulation 77: I40 -I54, 1988.
53. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin IIforming enzyme in the human heart. J Biol Chem 265: 22348-22357, 1990.
54. Veerappan A, Reid AC, Estephan R, O'Connor N, Thadani-Mulero M, Salazar-Rodriguez M, Levi R, Silver RB. Mast cell renin and a local renin-angiotensin system in the airway: role in bronchoconstriction. Proc Natl Acad Sci USA 105: 1315-1320, 2008.
55. Wagner J, Jan Danser AH, Derkx FH, de Jong TV, Paul M, Mullins JJ, Schalekamp MA, Ganten D. Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br J Ophthalmol 80: 159-163, 1996.
56. Wen JG, Frokiaer J, Jorgensen TM, Djurhuus JC. Obstructive nephropathy: an update of the experimental research. Urol Res 27: 29-39, 1999.
57. Wolf G, Butzmann U, Wenzel UO. The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron Physiol 93: P3-P13, 2003.